Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company based in Canada. The company provides a range of pharmaceutical products. Its offerings include Epuris (isotretinoin), an oral retinoid for severe nodular, inflammatory, conglobate, and recalcitrant acne. It also offers Actikerall, a topical solution for Grade I/II hyperkeratotic actinic keratosis of the face, forehead, and balding scalp, and Vaniqa, a topical cream to slow unwanted facial hair growth in women. Other products include Durela, an opioid analgesic for moderate to moderately severe pain in adults; Brinavess for rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for acute coronary syndrome; and Natroba for topical treatment of head lice and scabies infestations in adult and pediatric patients. Cipher Pharmaceuticals also has licensed products such as Absorica, an oral retinoid for severe nodular, inflammatory, conglobate, and recalcitrant acne; Conzip, an opioid agonist for moderate to moderately severe chronic pain in adults; and Lipofen, an adjunctive therapy to diet for reducing elevated LDL-C, total-C, triglycerides, and Apo B, and increasing HDL-C. The company's pipeline includes piclidenoson CF-101 for moderate to severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical terbinafine formulation in phase 3 clinical trials for onychomycosis; and DTR-001, a tattoo removal cream. The company was founded in 2000 and is headquartered in Mississauga, Canada.